Drug Profile
Tedalinab
Alternative Names: GRC-10693Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Anti-inflammatories; Antirheumatics; Indazoles; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory pain; Neuropathic pain; Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammatory-pain in India
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in European Union (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis in India